JPWO2020221277A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020221277A5 JPWO2020221277A5 JP2021564186A JP2021564186A JPWO2020221277A5 JP WO2020221277 A5 JPWO2020221277 A5 JP WO2020221277A5 JP 2021564186 A JP2021564186 A JP 2021564186A JP 2021564186 A JP2021564186 A JP 2021564186A JP WO2020221277 A5 JPWO2020221277 A5 JP WO2020221277A5
- Authority
- JP
- Japan
- Prior art keywords
- days
- body weight
- saturated
- partially unsaturated
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037396 body weight Effects 0.000 claims 66
- 150000001875 compounds Chemical class 0.000 claims 17
- 229920006395 saturated elastomer Polymers 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 7
- 150000001204 N-oxides Chemical class 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 7
- 239000002207 metabolite Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 229940002612 prodrug Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- -1 cyclic hydrocarbyls Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 206010013990 dysuria Diseases 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/085209 | 2019-04-30 | ||
| CN2019085209 | 2019-04-30 | ||
| PCT/CN2020/087689 WO2020221277A1 (zh) | 2019-04-30 | 2020-04-29 | 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022531570A JP2022531570A (ja) | 2022-07-07 |
| JP2022531570A5 JP2022531570A5 (https=) | 2023-05-11 |
| JPWO2020221277A5 true JPWO2020221277A5 (https=) | 2023-05-11 |
| JP7663508B2 JP7663508B2 (ja) | 2025-04-16 |
Family
ID=73028778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564186A Active JP7663508B2 (ja) | 2019-04-30 | 2020-04-29 | ジアミノピリミジン化合物を使用することによって、子宮内膜症性疼痛を治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12605381B2 (https=) |
| EP (1) | EP3960178B1 (https=) |
| JP (1) | JP7663508B2 (https=) |
| KR (1) | KR102935431B1 (https=) |
| CN (1) | CN114007620B (https=) |
| AU (1) | AU2020266947B2 (https=) |
| BR (1) | BR112021021838A8 (https=) |
| CA (1) | CA3138238A1 (https=) |
| MX (1) | MX2021013347A (https=) |
| SG (1) | SG11202111960PA (https=) |
| TW (1) | TWI737285B (https=) |
| WO (1) | WO2020221277A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7207634B2 (ja) | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
| US20250032476A1 (en) * | 2021-11-05 | 2025-01-30 | The Regents Of The University Of California | Alpha-2a adrenergic receptor modulators and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| MA43821A (fr) * | 2016-03-14 | 2018-11-28 | Afferent Pharmaceuticals Inc | Pyrimidines et variantes de celles-ci, et leurs utilisations |
| MA44489A (fr) | 2016-03-25 | 2019-01-30 | Afferent Pharmaceuticals Inc | Pyrimidines et variants de celles-ci, et leurs utilisations |
| JP7207634B2 (ja) * | 2017-11-01 | 2023-01-18 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 |
| USD956213S1 (en) | 2020-10-02 | 2022-06-28 | Phillips-Medisize A/S | Autoinjector |
-
2020
- 2020-04-29 SG SG11202111960PA patent/SG11202111960PA/en unknown
- 2020-04-29 US US17/607,475 patent/US12605381B2/en active Active
- 2020-04-29 CA CA3138238A patent/CA3138238A1/en active Pending
- 2020-04-29 KR KR1020217038622A patent/KR102935431B1/ko active Active
- 2020-04-29 EP EP20798599.5A patent/EP3960178B1/en active Active
- 2020-04-29 JP JP2021564186A patent/JP7663508B2/ja active Active
- 2020-04-29 WO PCT/CN2020/087689 patent/WO2020221277A1/zh not_active Ceased
- 2020-04-29 BR BR112021021838A patent/BR112021021838A8/pt unknown
- 2020-04-29 AU AU2020266947A patent/AU2020266947B2/en active Active
- 2020-04-29 MX MX2021013347A patent/MX2021013347A/es unknown
- 2020-04-29 CN CN202080032509.8A patent/CN114007620B/zh active Active
- 2020-04-30 TW TW109114698A patent/TWI737285B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7772278B2 (en) | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | |
| ES2617628T5 (es) | Régimen de dosificación para un agonista selectivo del receptor de S1P1 | |
| US6294517B1 (en) | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use | |
| CN1270718C (zh) | 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 | |
| IE870973L (en) | Synergistic combination product | |
| JP2009533457A (ja) | Ｃ−ニトロソから誘導されるニトロキシル供与体 | |
| KR20210137086A (ko) | 지방간 질환 및/또는 지방간염의 치료 방법 | |
| JP2002524498A (ja) | 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用 | |
| US6476074B1 (en) | Method and composition for treatment of erectile dysfunction | |
| RU2003105159A (ru) | Способ лечения климактерических расстройств у женщин во время или после менопаузы | |
| JP2012131829A (ja) | そう痒状態の処置のためのｍｇｌｕｒ５アンタゴニストの使用 | |
| US20130317048A1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| US20080161389A1 (en) | Method of treating ocular hypertension and intestinal disorders by using dianhydrohexite mononitrate derivatives | |
| US6562868B1 (en) | Method for treatment of female sexual dysfunction | |
| US6232331B1 (en) | Benzofuroxan derivatives, their therapeutic uses and pharmaceutical compositions | |
| JPWO2020177587A5 (https=) | ||
| JPWO2020259528A5 (https=) | ||
| CZ285633B6 (cs) | Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek | |
| JPWO2020221277A5 (https=) | ||
| JP2007506784A (ja) | 双極性障害およびその他の認知障害の治療における、ケレリトリン、その類似体およびそれらの使用 | |
| KR20010013387A (ko) | 통증을 치료하기 위한 드라플라진-유사체의 용도 | |
| US20050065161A1 (en) | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses | |
| JP2010526073A (ja) | 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体 | |
| JPWO2020221274A5 (https=) | ||
| EP0439320A1 (en) | Erectile dysfunction treatment |